文献速递肝病消化道肿瘤与早癌

信迪利单抗联合贝伐珠单抗及放疗一线治疗肝癌合并门静脉癌栓的二期研究

Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
PubMed 文献 · Hepatology · 2024-02-15

这项多中心单臂二期研究纳入46例肝癌合并门静脉癌栓患者,一线接受信迪利单抗联合贝伐珠单抗及放疗。客观缓解率58.7%,疾病控制率100%,中位总生存24.0个月,中位无进展生存13.8个月,安全性可接受。PCTMD1突变预示更短生存。

要点

  • 信迪利单抗+贝伐珠单抗+放疗一线治疗肝癌合并门静脉癌栓客观缓解率达58.7%。
  • 中位总生存24.0个月,中位无进展生存13.8个月,疾病控制率100%。
  • PCTMD1突变可预测更短的总生存和无进展生存。

核心结论

  • 信迪利单抗联合贝伐珠单抗及放疗一线治疗肝癌合并门静脉癌栓显示出良好的治疗反应和生存获益,安全性可接受。

研究设计与样本

  • 开放标签、多中心、单臂二期临床试验,在中国3家三级医院开展,共纳入46例肝癌合并门静脉癌栓患者。

主要发现

  • 客观缓解率为58.7%,疾病控制率为100%。
  • 中位随访26.0个月(95%CI:24.0-26.0),中位总生存24.0个月(95%CI:19.0-不适用),中位无进展生存13.8个月(95%CI:12.0-21.0)。
  • 未发生意料之外的不良事件或治疗相关死亡。
  • PCTMD1突变预示更短的总生存和无进展生存。

关键数值与推荐

  • 信迪利单抗200 mg静脉注射第1天,贝伐珠单抗15 mg/kg第1天,入组后3天内完成第一周期。
  • 放疗剂量30-50 Gy/10次,在2周期信迪利单抗+贝伐珠单抗后开始。
  • 放疗期间中断信迪利单抗+贝伐珠单抗,放疗后2周恢复,此后每3周一次,直至疾病进展、不可接受毒性或撤回知情同意。

临床怎么用

  • 该联合方案可作为肝癌合并门静脉癌栓患者的一线治疗选择之一,需注意放疗期间暂停信迪利单抗和贝伐珠单抗。

局限性

  • 单臂设计,无对照组,样本量46例,结论需随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Systemic treatments are listed as first-line therapies for HCC with portal vein tumor thrombus (PVTT), resulting in modest efficacy. We aimed to evaluate the efficacy and safety of sintilimab plus bevacizumab combined with radiotherapy in HCC with PVTT and to identify prognostic biomarkers. APPROACH AND RESULTS: This open-label, multicenter, single-arm, phase 2 clinical trial was conducted at 3 tertiary hospitals in China. A total of 46 patients with HCC with PVTT were enrolled. All the patients received the first cycle of i.v. sintilimab (200 mg, day 1) plus bevacizumab (15 mg/kg, day 1) within 3 days after enrollment. Radiotherapy (30-50 Gy/10 fractions) was administered after 2 cycles of Sin-Bev. Sin-Bev was disrupted during radiotherapy and resumed 2 weeks after radiotherapy and continued every 3 weeks thereafter until disease progression, unacceptable toxicity, or withdrawal of consent. The primary end point was objective response rate. Patients obtained an objective response rate of 58.7% and a disease control rate of 100%. After a median follow-up time of 26.0 months (95% CI: 24.0-26.0), the median OS was 24.0 months (95% CI: 19.0 to not applicable) and the median progression-free survival was 13.8 months (95% CI: 12.0-21.0), respectively. No unexpected adverse events or treatment-related deaths occurred. Mutations of PCTMD1 were predictive of shorter OS and progression-free survival. CONCLUSIONS: Sintilimab plus bevacizumab combined with radiotherapy provides favorable treatment response and survival outcomes along with an acceptable safety profile in the first-line setting for patients with HCC with PVTT (ClinicalTrials.gov Identifier: NCT05010434).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zhu M, Liu Z, Chen S, et al. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study. Hepatology. 2024. PMID: 38358542. doi:10.1097/HEP.0000000000000776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。